Forest Laboratories, Inc.
The Quarter in Detail
Savella, which is approved for the management of fibromyalgia, posted sales of $23.7 million, up significantly from the year-earlier sales of $17.4 million.
Savella was launched in late April 2009. We believe the product may have multi-hundred million dollar potential.
In early October 2010, Savella was moved into tier II unrestricted coverage on several managed care organizations. Improved formulary access should help boost sales. Forest Labs entered into a collaboration and distribution agreement with Janssen to commercialize Savella in Canada.
Savella sales are expected to grow 31%.
http://www.zacks.com/stock/news/51551/Forest+Tops+Again,+Provides+Outlook+
The Quarter in Detail
Savella, which is approved for the management of fibromyalgia, posted sales of $23.7 million, up significantly from the year-earlier sales of $17.4 million.
Savella was launched in late April 2009. We believe the product may have multi-hundred million dollar potential.
In early October 2010, Savella was moved into tier II unrestricted coverage on several managed care organizations. Improved formulary access should help boost sales. Forest Labs entered into a collaboration and distribution agreement with Janssen to commercialize Savella in Canada.
Savella sales are expected to grow 31%.
http://www.zacks.com/stock/news/51551/Forest+Tops+Again,+Provides+Outlook+
No comments:
Post a Comment